Phase 3 N=293 Trial of CF101 to Treat Patients With Psoriasis
Plaque Psoriasis
Primary: Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks — 12; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=728 A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients
Arthritis, Rheumatoid
Primary: American College of Rheumatology (ACR) 20 Response Rate — 72.5; 74.3 Percentage of participants
Phase 3 N=180 A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel
Adult Male Hypogonadism
Primary: The Percentage of Subjects on Day 90 Whose Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL — 2.9; 4.7; 77.9; 85.5 percentage of participants
Phase 4 N=301 A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
HIV Prevention
Primary: Number of Participants With a Grade 2 or Higher Adverse Event by Cohort — 230; 0 Participants
Phase 3 N=7,513 Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Venous Thromboembolism (VTE)
Primary: Modified Intent-to-Treat (mITT) Cohort 1: Percentage of Participants Experiencing the Composite Event of Symptomatic Deep Vein Thrombosis (DVT), Non-fatal Pulmonary…
Phase 2 N=145 Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Participants With Both a Change From Baseline in Hyperhidrosis Disease Severity Scale (HDSS) Score by ≥ 2 Points and a Change From Baseline in Gravimetric…
Phase 2 N=19 Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
Melasma
Primary: Change in Melasma Area and Severity Index (MASI) Score — -11.4 units on a scale — p=0.006
Phase 4 N=19 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Multiple Sclerosis
Primary: Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported — 0; 0 infusion reactions
N/A N=385 OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits
Diabetes · Diabetic Macular Edema · Diabetic Retinopathy
Primary: Rates of Retina Care Referral for Patients With Diabetic Macular Edema — 44 Participants
Phase 3 N=39 Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
Hypercholesterolemia
Primary: Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy — 10.0; 84.2 percentage of participants — p=< 0.0001
Early Phase 1 N=2 Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
Schizophrenia · Bipolar Disorder
Primary: Positive and Negative Symptom Scores — 14.5; 11; 14.5; 14 units on a scale
N/A N=64 OPTIONS Spinal Cord Stimulation Programming Parameters
Pain, Intractable
Primary: Change in Average Overall Pain as Measured by the Diary-reported Numeric Pain Rating Scale (NPRS) Questionnaire — -3.7 units on a scale — p=<0.01
Phase 2 N=47 A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
Asthma
Primary: Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise…
Phase 4 N=60 Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6
PT-NANBH
Primary: Number of Participants With a Sustained Virologic Response (SVR) log10 HCV RNA PCR <25 IU/mL 12 Weeks Post-treatment — 19; 34; 4 Participants
Phase 3 N=933 Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
Alzheimer's Disease
Primary: Change in Cognition — 0.13; 0.47; 0.18 units on a scale — p=0.9591